logo BDSP

Base documentaire

  1. Haemophilus influenzae type b conjugate vaccines : a review of efficacy data.

    Article, Communication - En anglais

    International Conference on Haemophilus influenzae type b infection in Asia. Bali, IDN, 1996/12/17.


    The development of a vaccine against Haemophilus influenzae type b (Hib) was stimulated by its recognition as a major pathogen of early childhood.

    The first vaccine to be developed was composed of the capsular polysaccharide of the organism, polyribosylribitol phosphate (PRP), and although effective in older children, it failed to protect those<2 years of age, the group with the highest burden of disease.

    The conjugation of PRP to protein led to a group of vaccines with enhanced immunogenicity and the ability to induce immunologic memory and thus the potential to protect in infancy.


    To review the trials of Hib conjugate vaccines in which protective efficacy in infants has been assessed and the experience in countries in which Hib conjugate vaccines have been introduced into the routine infant immunization schedule.


    Each of the Hib conjugate vaccines [PRP-diphtheria toxoid conjugate (PRP-D), PRP conjugated to outer membrane protein of Neisseria meningitidis group B (PRP-OMP), PRP oligosaccharides conjugated to mutant diphtheria toxin CRM197, (HbOC) and PRP conjugated to tetanus toxoid (PRP-T) ] has been subjected to prospective clinical trials and all have demonstrated high protective efficacy with one exception : that of the least immunogenic vaccine, PRP-D, when used in a Native American population with a high level of natural disease. (...)

    Mots-clés Pascal : Haemophilus influenzae, Pasteurellaceae, Bactérie, Composé conjugué, Bactériose, Infection, Prévention, Immunoprophylaxie, Efficacité, Incidence, Finlande, Europe, Alaska, Etats Unis, Amérique du Nord, Amérique, Californie, Arizona, Angleterre, Grande Bretagne, Royaume Uni, Epidémiologie, Nourrisson, Homme, Haemophilus influenzae type b

    Mots-clés Pascal anglais : Haemophilus influenzae, Pasteurellaceae, Bacteria, Conjugated compound, Bacteriosis, Infection, Prevention, Immunoprophylaxis, Efficiency, Incidence, Finland, Europe, Alaska, United States, North America, America, California, Arizona, England, Great Britain, United Kingdom, Epidemiology, Infant, Human

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0032012

    Code Inist : 002B05A02. Création : 31/05/1999.